These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33301805)

  • 1. Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
    Hirotsu KE; Rana J; Wang JY; Raghavan SS; Rieger KE; Srinivas S; Fan AC; Kwong BY; Novoa RA; Zaba LC
    J Am Acad Dermatol; 2021 Dec; 85(6):1610-1611. PubMed ID: 33301805
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective review.
    Malik R; Xiang DH; Riew GJ; Sanchez-Melendez S; Afvari S; LeBoeuf NR; Nambudiri VE
    J Am Acad Dermatol; 2024 Oct; 91(4):753-755. PubMed ID: 38909660
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma.
    Wu S; Adamson AS
    Dermatol Online J; 2019 Feb; 25(2):. PubMed ID: 30865407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
    Bellmunt J; Nadal R
    Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Klümper N; Vera-Badillo FE; Eckstein M; Hadaschik B; Grünwald V
    Eur Urol; 2024 Sep; 86(3):280-281. PubMed ID: 38599990
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Chen DC; AlSaffar H; Graefen H; Perera S; Mazzone E; Perera ML; Lawrentschuk N; Murphy DG
    Eur Urol; 2024 Sep; 86(3):282-283. PubMed ID: 38631993
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Catalano M; Santoni M; Roviello G
    Eur Urol; 2024 Sep; 86(3):283. PubMed ID: 38744633
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
    Penny CL; Quow K; Rundle CW; Al-Rohil RN; Cardones AR; Kheterpal MK; Fresco AI
    Br J Dermatol; 2022 Jul; 187(1):126-127. PubMed ID: 35048357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatments for patients with progressive metastatic urothelial carcinoma.
    Rosenberg JE
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):180-183. PubMed ID: 33739967
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab plus enfortumab vedotin in urothelial cancer.
    Santoni M; Takeshita H; Massari F; Bamias A; Cerbone L; Fiala O; Mollica V; Buti S; Santoni A; Bellmunt J
    Nat Rev Urol; 2024 Jul; 21(7):387-388. PubMed ID: 38267716
    [No Abstract]   [Full Text] [Related]  

  • 12. The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.
    Apolo AB; Bellmunt J; Cordes L; Gupta S; Powles T; Rosenberg JE; Van Der Heijden MS
    ESMO Open; 2024 Sep; 9(9):103725. PubMed ID: 39236601
    [No Abstract]   [Full Text] [Related]  

  • 13. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
    Benjamin DJ; Rezazadeh Kalebasty A; Prasad V
    Eur Urol Oncol; 2024 Jun; 7(3):313-315. PubMed ID: 38485615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
    Brown JR; Koshkin VS
    Eur Urol Focus; 2024 Mar; 10(2):231-233. PubMed ID: 38797658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer.
    Niegisch G
    N Engl J Med; 2024 Mar; 390(10):944-946. PubMed ID: 38446680
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
    Azizi A; Houshyar R; Mar N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1226-1229. PubMed ID: 35043748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab-associated vitiligo-like leukoderma in a patient with transitional cell carcinoma.
    Turner N; Leventhal J
    Int J Dermatol; 2018 Oct; 57(10):e90-e92. PubMed ID: 30091457
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Bedke J; Maas M
    Eur Urol; 2021 Aug; 80(2):257-258. PubMed ID: 33895011
    [No Abstract]   [Full Text] [Related]  

  • 20. Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.
    Taoka R; Kamada M; Izumi K; Tanimoto R; Daizumoto K; Hayashida Y; Uematsu K; Arai H; Sano T; Saito R; Hirama H; Kobayashi T; Honda T; Osaki Y; Abe Y; Naito H; Tohi Y; Matsuoka Y; Kato T; Okazoe H; Ueda N; Sugimoto M
    Int J Clin Oncol; 2024 May; 29(5):602-611. PubMed ID: 38418804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.